<DOC>
	<DOC>NCT00439777</DOC>
	<brief_summary>This is a multicenter, randomized, open-label, assessor-blind, event-driven, non-inferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic pulmonary embolism (PE) with or without symptomatic Deep-Vein Thrombosis (DVT) (Einstein-PE).</brief_summary>
	<brief_title>Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study</brief_title>
	<detailed_description>Within the US 'Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.' is sponsor.</detailed_description>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Factor Xa Inhibitors</mesh_term>
	<criteria>Confirmed acute symptomatic proximal PE with or without symptomatic DVT Legal lower age limitations (country specific) Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT and/or PE Other indication for VKA than DVT and/or PE The prerandomization anticoagulant treatment (Criteria # 4) has been prolonged from 36 hours to a maximum of 48 hours.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>